The OXiGENE Inc (NASDAQ:OXGN) recently announced positive top line results derived from randomised phase 2 clinical trial of Avastin (bevacizumab) with or without ZYBERESTAT for treating patients with recurring ovarian cancer. This study is known to be as Gynecologic Oncology Group Protocol 186I. This trial was conducted by GOG under its sponsors Cancer Therapy Evaluation Program of National Cancer Institute. OXiGENE Inc (NASDAQ:OXGN) shares after opening at $4.22 moved to $4.44 on last trade day and at the end of the day closed at $4.26. Company price to sales ratio in past twelve months was calculated as 112.46 and price to cash ratio as 1.28. OXiGENE Inc (NASDAQ:OXGN) showed a positive weekly performance of 106.80%.
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) and Bristol-Myers Squibb Company (NYSE:BMY) announced that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform. Five Prime Therapeutics Inc (NASDAQ:FPRX) shares advanced 22.61% in last trading session and ended the day on $22.29. FPRX return on equity ratio is recorded as 64.90% and its return on assets is -91.50%.
Fibrocell Science (NYSEMKT:FCSC) announced that David Pernock chairman and chief executive officer of Fibrocell Science will present at the Barclays Global Healthcare Conference 2014 at 2:30 pm EDT on Wednesday March 12 2014 at the Loews Hotel in Miami. Mr. Pernock will discuss the company’s autologous fibroblast technology its therapeutic candidates in development and its collaboration with Intrexon Corporation (NYSE:XON) to develop genetically-modified personalized biologics. Fibrocell Science Inc (NYSEMKT:FCSC) shares moved down -6.45% in last trading session and was closed at $5.80, while trading in range of $3.03-$7.20. Fibrocell Science Inc (NYSEMKT:FCSC) year to date performance is 42.86%.
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced the underwriters’ full exercise of the option granted to the underwriters to purchase an additional 786,750 shares of the company’s common stock, at a price to the public of $9.15 per share. The option to purchase the additional shares was granted in connection with the company’s previously announced underwritten public offering of 5,245,000 shares of its common stock. Ignyta Inc (NASDAQ:RXDX) weekly performance is 12.10%. On last trading day company shares ended up $10.19. Ignyta Inc (NASDAQ:RXDX) distance from 50-day simple moving average is -20.45%.